Arena Pharmaceuticals (NASDAQ:ARNA) posted its Q3 results, and while there was no ground-breaking news regarding its obesity drug, Belviq, the company did announce a new partnership with South Korean drugmaker Ildong. Arena already has a deal in place with Japanese pharma giant Eisai to market Belviq in major drug markets throughout the Americas.

In the following video, health care analysts Max Macaluso and David Williamson take a close look at the details of this partnership and also discuss the merits of Arena's international strategy.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium advisory service. We’re motley! Questioning an investing thesis -- even one of our own -- helps us all think critically about investing and make decisions that help us become smarter, happier, and richer.